Evidence map›Paper›PMID 27279710›Full record

ArticlePharmacognosy magazine2016

Pyrostegia venusta (Ker Gawl.) Miers Crude Extract and Fractions: Prevention of Dental Biofilm Formation and Immunomodulatory Capacity.

Mayara Brito de Sousa, José Otávio Carrera Silva Júnior, Wagner Luiz Ramos Barbosa, Erika da Silva Valério, Andriele da Mata Lima, Marlon Heggdorne de Araújo, Michelle Frazão Muzitano, Celso Vataru Nakamura, João Carlos Palazzo de Mello, Francisco Martins Teixeira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacognosy magazine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mayara Brito de SousaDepartment of Post-Graduation Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará, Augusto Corrêa Avenue, No. 01, University Campus of Guamá, Belém, Pará CEP 67150-110, Brazil.
José Otávio Carrera Silva JúniorDepartment of Post-Graduation Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará, Augusto Corrêa Avenue, No. 01, University Campus of Guamá, Belém, Pará CEP 67150-110, Brazil; Laboratory of Research and Development in Pharmaceutical and Cosmetic, College of Pharmacy, Institute of Health Sciences, Federal University of Pará, Augusto Corrêa Avenue, No. 01, University Campus of Guamá, Belém, Pará CEP 67150-110, Brazil.
Wagner Luiz Ramos BarbosaDepartment of Post-Graduation Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará, Augusto Corrêa Avenue, No. 01, University Campus of Guamá, Belém, Pará CEP 67150-110, Brazil.
Erika da Silva ValérioDepartment of Post-Graduation Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará, Augusto Corrêa Avenue, No. 01, University Campus of Guamá, Belém, Pará CEP 67150-110, Brazil.
Andriele da Mata LimaCollege of Pharmacy, Institute of Health Sciences, Federal University of Pará, Augusto Corrêa Avenue, No. 01, University Campus of Guamá, Belém, Pará CEP 67150-110, Brazil.
Marlon Heggdorne de AraújoLaboratory of Bioactive Products, School of Pharmacy, Federal University of Rio de Janeiro, Campus Macaé, Polo Novo Cavaleiros - IMCT, Alcides da Conceição Street, 159 Novo Cavaleiros, CEP 27933-378, Brazil.
Michelle Frazão MuzitanoLaboratory of Bioactive Products, School of Pharmacy, Federal University of Rio de Janeiro, Campus Macaé, Polo Novo Cavaleiros - IMCT, Alcides da Conceição Street, 159 Novo Cavaleiros, CEP 27933-378, Brazil.
Celso Vataru NakamuraDepartment of Post-Graduation Program in Pharmaceutical Sciences, Health Sciences Center, State University of Maringá, Av. Colombo, 5790, Maringá, Paraná CEP 87020-900, Brazil.
João Carlos Palazzo de MelloDepartment of Post-Graduation Program in Pharmaceutical Sciences, Health Sciences Center, State University of Maringá, Av. Colombo, 5790, Maringá, Paraná CEP 87020-900, Brazil.
Francisco Martins TeixeiraDepartment of Post-Graduation Program in Pharmaceutical Sciences, Institute of Health Sciences, Federal University of Pará, Augusto Corrêa Avenue, No. 01, University Campus of Guamá, Belém, Pará CEP 67150-110, Brazil; Pharmacy Course, Federal University of Rio de Janeiro, Campus Macaé, Av. Aluízio da Silva Gomes, 50 Granja dos Cavaleiros, CEP 27930-560, Macaé, Rio de Janeiro, CEP 87020-900, Brazil.
Universidade Federal do Pará · BRUniversidade Estadual de Maringá · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCaries and periodontal diseases remain as important diseases in the Brazilian population. One important pathogen associated with this situation is Streptococcus mutans and other important factor is this pathogen's ability to adhere firmly to the tooth surface leading to dental biofilm formation and caries development.

objectivesDetermine the antibacterial and other biological activities of P. venusta related to its potential to be used in the treatment of caries and periodontal disease.

methodsThe growth inhibition by P. venusta of Streptococcus mutans, S. mitis, S. oralis and Candida albicans was determined using the broth microdilution method. In addition, the effect of the samples in adherence and reducing production of acids by S. mutans, and germ-tube formation of C. albicans was analysed. The Nitric Oxide (NO) production and cytotoxicity of P. venusta to peripheral blood mononuclear cells (PBMC) and RAW 264.7 Cell Line Murine Macrophage from Blood were assessed.

resultsThe crude extract (CE) and ethyl-acetate (AF) and n-butanol (BF) fractions showed antibacterial activity. The ethyl-acetate (AF) fraction showed the highest inhibition percentage against the adherence of S. mutans and C. albicans cells without budding, beyond NO production inhibition. There was not any cytotoxicity in the murine macrophages RAW 264.7 cells.

conclusionOur results suggest that P. venusta presents potential to be used as a preliminary source of compounds that can provide helpful activity when used in prophylaxis or treatment of caries or periodontal disease. SUMMARY: Biological activities of Pyrostegia venusta and its potential for use in formulations for the prevention of oral diseases. Abbreviations used: NO: Nitric oxide, PBMC: Peripheral blood mononuclear cells, CE: Crude extract, AF: Ethyl-acetate fraction, BF: n-butanol fraction, HF: Hexane fraction, WF: Water fraction, MIC: Minimum inhibitory concentration, MBC: Minimum bactericidal concentration, ATCC: American Type Culture Collection, CFU: Colony-forming units, BHI: Brain heart infusion, RPMI: Roswell Park Memorial Institute, MOPS: 3-(N-morpholino)propanesulfonic acid, DMEM: Dulbecco's modified Eagle's médium, LPS: Lipopolysacharide, MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide, OD: Optical density, AC: Acteoside.

Indexed as

Anti-bacterial agentsCandida spp.cariesperiodontal diseaseStreptococcus spp

Identifiers

PMID27279710
PMCPMC4883082
OpenAlexW2332872892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.